Wang Yu, Leng Hui, Chen Hui, Wang Lei, Jiang Nan, Huo Xin, Yu Bin
Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China.
Oncol Res. 2016;24(5):361-369. doi: 10.3727/096504016X14685034103310.
Ubiquitin-conjugating enzyme E2T (UBE2T), a member of the E2 family, was found to be overexpressed in a great many cancers such as bladder cancer, lung cancer, and prostate cancer. However, there have been no reports on the role of UBE2T in osteosarcoma. In this study, we tried to make the effects of UBE2T on osteosarcoma clear. The study results showed that UBE2T was overexpressed in osteosarcoma tissues and cell lines. Moreover, UBE2T knockdown inhibited osteosarcoma cell proliferation, migration, and invasion. We also observed that UBE2T downregulation could suppress the activity of the PI3K/Akt signaling pathway. Therefore, we concluded that UBE2T exerted its inhibitory effects on osteosarcoma cells via suppressing the PI3K/Akt signaling pathway. These findings indicated that UBE2T may be a potential therapeutic target for osteosarcoma treatment.
泛素结合酶E2T（UBE2T）是E2家族的一员，被发现在许多癌症中过度表达，如膀胱癌、肺癌和前列腺癌。然而，关于UBE2T在骨肉瘤中的作用尚无报道。在本研究中，我们试图明确UBE2T对骨肉瘤的影响。研究结果表明，UBE2T在骨肉瘤组织和细胞系中过度表达。此外，敲低UBE2T可抑制骨肉瘤细胞的增殖、迁移和侵袭。我们还观察到，下调UBE2T可抑制PI3K/Akt信号通路的活性。因此，我们得出结论，UBE2T通过抑制PI3K/Akt信号通路对骨肉瘤细胞发挥抑制作用。这些发现表明，UBE2T可能是骨肉瘤治疗的一个潜在治疗靶点。
